department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog news

Browse

187 stories matching this filter · ← front page

★ save view ↓export CSV

rangeto

sort

recent oldest source alpha

source

STAT776 Endpoints579 BioPharma Dive223 onclive165 Fierce Biotech53 BioSpace52 raps22

therapy area

all Oncology81 Cardiology27 Psychiatry & CNS21 Vaccines17 Immunology17 Rare Disease12 Hepatology6 Hematology

<![CDATA[Future Directions in Relapsed and Refractory Multiple Myeloma ]]>
<![CDATA[]]>
onclive · 2mo ago↗ source
<![CDATA[Dr Parikh on the Feasibility and Importance of Immunotherapy Trials in Anal Cancer ]]>
<![CDATA[Aparna R. Parikh, MD, discusses how trials like PODIUM-303 are reshaping the treatment paradigm for squamous cell anal carcinomas. ]]>
onclive · 2mo ago↗ source
<![CDATA[Sequencing Strategies After Progression in Multiple Myeloma ]]>
<![CDATA[]]>
onclive · 2mo ago↗ source

page 5 of 8

6

Infectious Disease4

<![CDATA[EGFR-Mutated NSCLC: Targeting MET-Driven Resistance in Second-Line Therapy]]>

<![CDATA[In this segment, Dr. Sands asks Dr. Wakelee to discuss how emerging data on MET-driven resistance mechanisms are shaping second-line treatment decisions in EGFR-mutated non-small cell lung…

onclive · 2mo ago↗ source

<![CDATA[Sequencing ADCs in Endometrial Cancer]]>

<![CDATA[Sequencing therapy in recurrent endometrial cancer is becoming more complicated as immunotherapy moves earlier and antibody drug conjugates gain momentum.]]>

onclive · 2mo ago↗ source

<![CDATA[Second Clinical Scenario - Progressive Disease Despite Hematocrit Control]]>

<![CDATA[Polycythemia vera symptoms like fatigue and aquagenic itching signal active disease; experts urge objective tracking and tailored therapy beyond phlebotomy.]]>

onclive · 2mo ago↗ source

<![CDATA[Real-World Data Highlight Survival Benefit of Rituximab Maintenance After Frontline BR in MCL]]>

<![CDATA[Rituximab following first-line bendamustine demonstrated significant OS and EFS real-world benefits in mantle cell lymphoma.]]>

onclive · 2mo ago↗ source

<![CDATA[Dr Silbermann on Clinical Trial Design Considerations in Multiple Myeloma]]>

<![CDATA[Rebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.]]>

onclive · 2mo ago↗ source

<![CDATA[Retrospective Data Show Potential Real-World TTNT and OS Improvements With Next-Generation BTK Inhibitors in R/R MCL]]>

<![CDATA[Retrospective data showed zanubrutinib was associated with improved real-world overall survival vs ibrutinib in second- or third-line mantle cell lymphoma.]]>

onclive · 2mo ago↗ source

<![CDATA[MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors]]>

<![CDATA[Roswell Park Comprehensive Cancer Center launched a phase 2 trial evaluating SurVaxM plus temozolomide in progressing neuroendocrine tumors.]]>

onclive · 2mo ago↗ source

<![CDATA[INBRX-106 Plus Pembrolizumab Yields Efficacy Benefit vs Pembrolizumab Alone in First-Line HNSCC]]>

<![CDATA[First-line INBRX-106 plus pembrolizumab generated a higher ORR vs pembrolizumab monotherapy in PD-L1–positive metastatic or unresectable HNSCC.]]>

onclive · 2mo ago↗ source

<![CDATA[Treatment Intensification Gains Momentum in mCSPC Management]]>

<![CDATA[During a recent OncLive Peer Exchange, prostate cancer experts discussed the evolving role of treatment intensification in mCSPC.]]>

onclive · 2mo ago↗ source

<![CDATA[FDA Approval of Brexu-Cel for R/R MCL Calls for Raised Awareness of CAR T-Cell Therapy Safety Considerations]]>

<![CDATA[Luhua (Michael) Wang, MD, discusses the FDA approval of brexu-cel in mantle cell lymphoma and what to know about CAR T-cell therapy in clinical practice.]]>

onclive · 2mo ago↗ source

<![CDATA[Dr Randall on the Rationale for Investigating CSF-1R Inhibition in TGCT]]>

<![CDATA[R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.]]>

onclive · 2mo ago↗ source

<![CDATA[Renal Cell Carcinoma: Real-World Factors in First-Line Treatment Selection]]>

<![CDATA[In this segment, Dr. Elizabeth Plimack and Dr. Yasser Ged discuss how real-world patient factors influence first-line treatment decisions in renal cell carcinoma. ]]>

onclive · 2mo ago↗ source

<![CDATA[Expanding ctDNA Applications to RCC and Germ Cell Tumors]]>

<![CDATA[Experts explain how ctDNA tracking in metastatic cancer guides therapy tweaks, flags relapse early, and where it fails in brain/peritoneal disease.]]>

onclive · 2mo ago↗ source

<![CDATA[RAPNO Criteria and MRI Assessment in PLGG: Recommendations vs. Real-World Practice]]>

<![CDATA[Learn how clinicians weigh symptoms, MRI changes and family goals to decide when a child’s tumor needs treatment—beyond simple size cutoffs.]]>

onclive · 2mo ago↗ source

<![CDATA[ctDNA in Metastatic Urothelial Carcinoma]]>

<![CDATA[Experts explain how ctDNA tracking in metastatic cancer helps tailor immunotherapy, spot relapse early, and guide dose breaks—plus key limitations.]]>

onclive · 2mo ago↗ source

<![CDATA[Institutional Perspectives on Treatment Thresholds in PLGG]]>

<![CDATA[Experts weigh PLGG treatment choices, balancing chemo and MEK inhibitors, guided by vision decline, symptoms, tumor growth, and family logistics.]]>

onclive · 2mo ago↗ source

<![CDATA[Renal Cell Carcinoma: Practical Treatment Selection Across Risk Groups]]>

<![CDATA[In this segment, Dr. Elizabeth Plimack leads a discussion with Dr. Sundhar Ramalingam and Dr. Yasser Ged on how clinicians approach treatment selection in renal cell carcinoma across diffe…

onclive · 2mo ago↗ source

<![CDATA[Nivolumab Plus SOC Therapy Shows Encouraging Disease Control in Grade Group 5 Prostate Cancer]]>

<![CDATA[The regimen produced a 2-year freedom from biochemical recurrence rate of 90.3% in grade group 5 prostate cancer.]]>

onclive · 2mo ago↗ source

<![CDATA[Five Under 5: Top Oncology Videos for the Week of 5/3]]>

<![CDATA[The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.]]>

onclive · 2mo ago↗ source

<![CDATA[ADCs Reshape the Future of Lung Cancer Care: From Second-Line Therapy to Earlier Intervention]]>

<![CDATA[Judy Wang, MD, discusses how ADCs are transforming NSCLC treatment with improved responses, biomarker-driven care, and CNS activity.]]>

onclive · 2mo ago↗ source

<![CDATA[The OncFive: Top Oncology Articles for the Week of 5/3]]>

<![CDATA[The FDA clears zenocutuzumab in NRG1 fusion+ cholangiocarcinoma, accepts a taletrectinib NDA in ROS1+ NSCLC for review, and more.]]>

onclive · 2mo ago↗ source

<![CDATA[Dr Randall on Long-Term Responses and Functional Benefits With Pimicotinib in TGCT]]>

<![CDATA[R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.]]>

onclive · 2mo ago↗ source